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INTRODUCTION
Allogeneic HLA-matched hematopoietic stem cell transplantation (allo-SCT) and subsequent donor lymphocyte infusion (DLI) to eradicate persistent or relapsed malignant cells are considered an effective curative treatment for patients with high-risk hematological malignancies or patients who fail to respond to chemotherapy [1] . The curative potential of this therapy has been attributed to the recognition of malignant cells by donor T-cells. Detailed analyses of T-cell immune responses in patients responding to DLI have demonstrated that the donor T-cells recognize minor histocompatibility antigens (MiHA) presented in the context of HLA-molecules on malignant cells. MiHA are peptides derived from polymorphic proteins that differ between donor and recipient due to single nucleotide polymorphisms (SNP) [2] [3] [4] [5] . Previously it has been demonstrated that T-cells directed against MiHA that are ubiquitously expressed can mediate lifethreatening graft-versus-host-disease (GVHD) [6] , whereas T-cells directed against MiHA with hematopoietic restriction may mediate graft-versus-leukemia (GVL) response in absence of GVHD [7] .
Although the introduction of various molecular and genomic technologies resulted in an increased number of HLA-class I restricted MiHA identified by forward immunological approaches, the number of MiHA with therapeutic relevance is still limited [8, 9] . A major limitation for clinical implementation of MiHA is the small number of identified MiHA derived from genes that are exclusively expressed in hematopoietic cells.
To allow the selective analysis of hematopoietic restricted MiHA, we and others have used reverse immunological approaches in which predicted polymorphic peptides are the starting point and peptide candidates are subsequently screened for their capacity to induce a specific T-cell response. This approach has the potential to specifically screen for T-cells recognizing MiHA that are exclusively expressed by hematopoietic cells.
However, it has been reported that when such peptide predictions are solely based on computer algorithms that predict peptide-HLA binding affinity and proteolytic cleavage, the detected T-cell responses are often directed against epitopes that are not naturally processed and presented and therefore fail to lyse malignant target cells [10] [11] [12] . To circumvent this peptide selection problem we and others previously introduced mass spectrometry (MS) based HLA-ligandomes as a reliable source for naturally processed and presented peptides and developed an algorithm that can be exploited to identify T-cells specific for potential clinically relevant MiHA [13, 14] .
The emerging availability of high quality SNP data in combination with the implementation of HLA-ligandomes provides a large supply of MiHA-candidates with guaranteed processing and HLA-restricted presentation at the cell surface [15] . We used our recently established algorithm [13] to select the top 25 MiHA candidates from our newly established large set of B-lymphocyte derived HLA-class I eluted peptides [16] .
To validate these MiHA candidates is essential to demonstrate their immunogenic potential by isolation of high avidity specific T-cells. We therefore screened the TCR repertoire of 16 unrelated donors for the presence of T-cells specific for these MiHA-candidates. MHC-multimer positive T-cells lines were generated from peripheral blood mononuclear cells (PBMC) by magnetic activated cell sorting (MACS). Flow cytometric analysis of antigen-specific T-cells, followed by functional testing of MHC-multimer sorted and expanded T-cell clones using both IFN-γ and GM-CSF as readout demonstrated the immunogenic potential of LB-CLYBL-1Y, LB-TEP1-1S and two previously described MiHA. For one of the newly defined MiHA we were able to confirm the biological relevance by demonstrating MHC-multimer positive T-cells in a patient suffering from AML after treatment with allo-SCT and subsequent DLI. Our data illustrate that with this reverse immunology approach biologically relevant MiHA can be identified as well as MiHA that are not frequently induced in vivo but can potentially be used for immunotherapeutic strategies.
EXPERIMENTAL PROCEDURE

Cell collection and culture conditions
Peripheral blood was obtained from different individuals after informed consent (Sanquin Reagents, Amsterdam and Leiden University Medical Center, Leiden, The Netherlands). All experiments were approved by the local medical ethics committees. Blood samples were HLA-typed by high-resolution genomic DNA-typing.
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll gradient separation and cryopreserved for further use. T-cells were cultured in T-cell medium consisting of Iscove's Modified Dulbecco's Media (IMDM: Lonza) supplemented with 5% human serum (HS), 5% fetal bovine serum (FBS), 100 IU/ml IL-2 (Proleukin), 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). Epstein-Barr virus-transformed lymphoblastoid B-cell lines (EBV-LCL) and phytohaemagglutinin (PHA; Murex Diagnostics) blasts were generated using standard procedures. The T2 cell line was cultured in IMDM with penicillin/ streptomycin and 5% FCS.
Peptide library of HLA-class I eluted peptides
The peptides used for this study are derived from a newly established large peptide library that has been recently described by Hassan et al [16] . In short: Peptide elution, reverse phase high-performance liquid chromatography (RP-HPLC), and tandem mass spectrometry (MS/MS) were carried out as previously described [17, 18] . Briefly, 60 x 109 HLA-A*0201 and HLA-B*0702 positive EBV-LCL were washed with ice cold PBS and pellets were stored at -80°C until use. Peptide-HLA-class I complexes were purified from cell lysate by affinity chromatography. Subsequently, peptides were eluted from HLA-molecules, and separated from the HLA heavy chain fragments and β2-microglobulin by size filtration. The peptide mixture was separated by various first dimension separation techniques, after which the peptides were measured by on-line nanoHPLC-
MS/MS.
Selection of MiHA-candidates from a set of eluted peptides
MiHA-candidates were selected based on our recently developed MiHA selection algorithm from the recently established peptide elution library [13] . Briefly, the tandem mass spectra of eluted peptides were submitted to the HSPVdb [19] , a database optimized for finding polymorphic peptides. To select for MiHA-candidates within this set we evaluated the polymorphic peptides using strict threshold scores for mass spectrometry defined sequence reliability (BMI≥30, ppm≤2.0), peptide length [8-11 amino acids), predicted peptide-HLA affinity (<500 nM), allele frequencies of the SNP encoding polymorphism (0.05-0.7%) and specific gene exclusion criteria (no extreme polymorphic genes). After confirming their integrity by comparing the tandem mass spectra of the synthetic peptides with that of the eluted counterparts the top 25 MiHA-candidates, with the highest threshold scores, were selected for further analysis.
Generation of peptide-MHC complexes
All peptides were synthesized in-house using standard Fmoc chemistry. Recombinant HLA-A*0201 and HLA-B*0702 heavy chain and β2m were in-house produced in Escherichia coli. MHC-class I refolding was performed as previously described with minor modifications [20] . MHC-class I complexes were purified by gel-filtration HPLC in PBS and stored at 4 ºC. The peptide HLA-A*0201 or HLA-B*0702 binding affinity was assessed by subjecting prefolded UV-sensitive peptide-MHC complexes (100 μg/ml) to 366 nm UV light (Camag) for 1 hr. in presence of the peptide of interest (200 μM) [21] . As controls the CMV PP65 NLVPM-VATV, CMV PP65 TPRVTGGAM, modified MART1 ELAGIGILTV and wild-type MART1 AAGIGILTV peptide were used. After exchange, samples were spun at 16,000g for 5 min and supernatants were used to assess HLA-monomer rescue using a bead assay as previously described [22] .
Isolation of MHC-multimer positive T-cells by MHC-multimer pull down
Prior to isolation PBMC samples were stained with PE-coupled MHC-multimers for 1 hour at 4 ºC. Subsequently, cells were washed and incubated with anti-PE beads (MiltenyiBiotec, BergischGladbach, Germany). 
PE
Cytokine secretion assay
For analysis of IFN-γ and GM-CSF production, 5000 T-cells were stimulated with 20,000 EBV-LCL or 10,000 fibroblasts loaded with different concentrations of peptides in 96-round bottomed well plates. Before stimulation, fibroblasts were either pre-treated with IFN-γ (100 IU/ml) or not for 5 days. For recognition of primary malignant cells, 1000 T-cells were stimulated with 5,000 malignant cells in a 384-well plate. After 18 hours, supernatants were harvested, and the concentration of IFN-γ and GM-CSF were measured by an enzymelinked immunosorbent assay (ELISA; Sanquin Reagents). An arbitrary detection limit was set to 100 pg/ml for both cytokines.
SNP genotyping and microarray gene expression analysis
A panel of 100 HLA-typed EBV-LCL was selected for SNP screening as previously described [9] . Briefly, genomic DNA was isolated of 5×106 EBV-LCL cells using GentraPuregene Cell Kit (Qiagen) and PCRfree whole genome amplification (WGA) was performed. The DNA samples were hybridized to Illumina Human1M-duo arrays. For gene expression analysis, total RNA was isolated using small and micro scale RNAqueous isolation kits (Ambion), and amplified using the TotalPrep RNA amplification kit (Ambion).
After preparation using the whole-genome gene expression direct hybridization assay (Illumina), cRNA samples were dispensed onto Human HT-12 v3 Expression BeadChips (Illumina) according to the manufacturer's protocol. Sample collection was performed as previously described [23] [24] [25] . Microarray gene expression data were analyzed using R 2.15.
RESULTS
Selection of high affinity HLA-A*0201 and B*0702 binding MiHA-candidates from a set of HLA-class
I eluted peptides
We have recently reported a MiHA selection algorithm to be able to select MiHA candidates from a library of HLA-class I eluted peptides [13] . This MiHA selection algorithm comprises several evaluation steps that are summarized in the material and methods section. This algorithm was used to screen our newly established library of eluted HLA-class I peptides derived from multiple HLA-A*0201 and B*0702 positive EBV-LCLs, to select for potential MiHA candidates [16] .To validate this newly established library of approximately 16.000 eluted HLA class I peptides comprising of mainly monomorphic peptides, we first screened for the presence of known MiHA. Peptide sequences or their relevant length variants were identified for 10 out of 13 MiHA that were expressed by the EBV-LCLs as revealed by SNP genotyping (Supplemental Table 1 ) [3, 8, 9] , illustrating the high quality of this peptide elution library.
HLA Peptide
Sequenceα Gene RS number SNP Allele Frequency A*02:01
B*07:02
In the next step we selected a set of 25 MiHA-candidates using the MiHA selection algorithm, including 22
novel MiHA-candidates as well as the previously reported LB-NISCH-1A, LB-ERAP1-1R and LB-GEMIN4-1V MiHA (Supplemental Table 2 ). We first analyzed the capacity of the 25 MiHA-candidates to stabilize a peptide-HLA complex in a HLA-binding assay that is based on UV-induced conditional ligand cleavage as described previously [10, 22, 26] . After UV-exchange, the HLA-binding affinity of the tested peptides was normalized to the high-affinity control peptides CMV-PP65-NLV and CMV-PP65-TPR for HLA-A*0201 and B*0702, respectively (Supplemental Figure 1 ). MiHA-candidates were selected when their HLA-binding affinity exceeded that of the MART1-WT-AAG peptide, which binds with low affinity to HLA-A*0201. HLA- binding affinity as measured with HLA-rescue scores exceeded that of the MART1-WT-AAG control for 8
HLA-A*0201 and 13 B*0702 binding MiHA-candidates. Peptide sequences and allele frequencies of the MiHA are shown in Table 1 .
Isolation of peripheral blood derived MHC-multimerpositive T-cells by MHC-multimer pull down
To validate the 21 peptides as MiHA with immunogenic potential,we generated MHC-multimers and analyzed Table 3 ). As demonstrated in Figure 1B , T-cells reactive with the CLYBL-1Y and LB-GEMIN4-1V
MHC-multimer were frequently detected in 8 of the 16 and 6 of the 9 enriched T-cell lines, respectively. In contrast, T-cells specific for the other MiHA appeared more restricted to a few donors.
Detection of high avidity T-cell clones by screening for MiHA-specific IFN-γ and GM-CSF production
Next, a total number of 806 MHC-multimer positive T-cell clones representing all detected T-cell populations was generated by FACS sorting. To demonstrate recognition of potential MiHA-candidates, all 806 T-cell clones were stimulated with specific antigen and cytokine production was determined as a measure for anti- gen specific reactivity. Because the T-cell clones were most likely derived from the naive T-cell repertoire and have presumably not all acquired the capacity to produce IFN-γ upon antigen encounter, we first screened all T-cell clones for their potential to secrete IFN-γ after αCD3/28 stimulation. As demonstrated in Figure 2A , the generated T-cell clones demonstrated a broad range of IFN-γ secretion. To investigate whether GM-CSF was of additional value to improve the screening efficiency, the GM-CSF production of part of the T-cell clones with variable IFN-γ secretion potential was measured after αCD3/28 stimulation. The results demonstrate that a substantial number of T-cell clones with poor intrinsic IFN-γ production was able to produce pronounced GM-CSF levels ( Figure 2B ). Therefore by using both IFN-γ and GM-CSF as a readout we could increase the number of MHC-multimer positive T-cell clones that could be screened. By setting an arbitrary detection limit to 100 pg/ml for both cytokines, 98% of generated T-cell clones could subsequently be screened for MiHA specific reactivity.
To demonstrate the capacity of the isolated MHC-multimer positive T-cell clones to recognize specific MiHA Figure 3A , B, C, D and E). MiHA specific T-cell clones demonstrated variable peptide avidity and half maximum cytokine production (IC50) varied between an IC50 of ±100 pM for the high avidity T-cell clone K156 specific for GEMIN4 ( Figure 3C ) and an IC50 of ±62.5 nM for the low avidity T-cell clone K337 specific for C18orf21 ( Figure 3E ). For the CLYBL-1Y MiHA candidate, MHC-multimer positive T-cell clones were successfully isolated from 4 different donors. High avidity CLYBL-1Y specific T-cell clones were isolated from donor ABM, whereas only low avidity or non-reactive T-cells were isolated from donor UDN, EPP and FHT respectively ( Figure 3A ). For the previously described MiHA ERAP1-1R, both high and low avidity T-cell clones were isolated from the 2 donors that demonstrated MHC-multimer positive T-cell populations after pull down. All T-cell clones that demonstrated peptide specific cytokine production were stimulated with a panel of 10 SNP genotyped HLA-A*0201 and B*0702 positive EBV-LCL target cells to screen for reactivity against Table 4 ).
Detection of MiHA specific T-cell responses in patients after allo-SCT
Tested patient samples were obtained during or after the peak response, 5 to 8 weeks after treatment with DLI .For the newly identified CLYBL-1Y MiHA, MHC-multimer positive T-cells were detected in 1 of the 3 screened patients ( Figure 4A ) with a frequency of 0.34% of total CD8 + T-cells at day 41 after DLI (AML patient MBF, Figure 4B ). For the previously described ERAP1-1R and GEMIN4-1V MiHA, MHC-multimer positive T-cells were detected in 1 of the 2 and 1 of the 4 screened patients (both multiple myeloma (MM) patient CUB at day 86), respectively ( Figure 4A,B) . Detected frequencies of circulating MHC-multimer positive T-cells ranged between 0.04% and 0.34% of total CD8 + T-cells. For the other 17 MiHA-candidates with validated HLA-binding affinity and SNP occurrence, including the newly identified MiHA TEP1-1S, no MHC-multimer positive T-cells were detected in the peripheral blood of 1 to 5 screened patients (Figure 4 A,B, Supplemental Table 4 ). (Figure 5A ), but a difference in TCR Vβ usage; clones derived from donor ABM expressed TCR Vβ22 and patient MBF derived clones were TCR-Vβ1 positive. Clone K264 and K2-339 were stimulated with T2 cells loaded with titrated concentrations of either the specific or the allelic variant peptide and IFN-γ production was measured ( Figure 5B ). Both T-cell clones demonstrated high CLYBL-1Y specific peptide reactivity, with IC50 varying between 1-4 pM, whereas the allelic CLYBL-1D
variant was not or hardly recognized by both T-cell clones, demonstrating that T-cell clones derived from an unprimed setting can be equally potent as T-cells derived from an in vivo primed setting.
CLYBL-1Y and TEP1-1S specific T-cell recognition of hematopoietic malignant cells
To investigate the expression pattern of the CLYBL and TEP1 genes we performed a microarray gene expression array using a panel of primary and cultured malignant (and non-malignant) hematopoietic and non-hematopoietic cells (Supplemental Figure 2) . The data showed that the CLYBL gene is broadly expressed in hematopoietic and non-hematopoietic cells. Expression of the TEP1 gene was not significantly measured in the majority of the samples. To investigate whether the CLYBL-1Y and TEP1-1S specific T-cell clones were able to recognize hematopoietic malignant cells they were stimulated with primary CML, AML and ALL cells derived from different MiHA positive and negative patients that were positive for the restricting HLA-molecule.
As a control, T-cell clones were also tested for recognition of EBV-LCL generated from the same individuals. These data indicate that the tested MiHA can be presented in the context of HLA at the surface of leukemic cells and may therefore serve as direct targets of CD8 + T-cells involved in a GVL response. In addition, the potential of the MiHA to serve as target in GVHD was estimated and the MiHA specific T-cell clones were tested for recognition of non-hematopoietic fibroblasts. To mimic the pro-inflammatory cytokine milieu, early after transplant or during potent GVHD responses, fibroblasts were pretreated with IFN-γ. Although both the CLYBLK264 and TEP1K091 T-cell clone poorly recognized non treated fibroblasts they clearly recognized those that were IFN-γ pretreated (Figure 6 B&D) . These data indicate that both CLYBL-1Y and TEP1-1S may be considered as MiHA with potential therapeutic value under non-inflammatory conditions, but they may participate in toxic GVHD responses in a pro-inflammatory environment.
DISCUSSION
In this study we demonstrate the identification of two biologically relevant MiHA by a reverse immunology approach. We started our approach by selecting MiHA-candidates from our recently generated B-lymphocyte derived HLA-class I eluted peptide library [13, 16] . MiHA, however, may be of therapeutic interest as they can be exploited in potential peptide vaccination or adoptive T-cell therapies when they demonstrate promising gene expression patterns.
A major limitation for the identification of large numbers of MiHA using a reverse immunology approach may be the low frequency of high avidity MiHA specific T-cells within an individual's T-cell repertoire. By performing two rounds of MHC-multimer enrichments each followed by a 10 days expansion step we increased the number of MHC-multimer positive T-cells that was isolated, since we observed that after the second enrichment round previously undetected MHC-multimer positive T-cell populations were found. In addition, by measuring GM-CSF in addition to IFN-γ as readout for T-cell reactivity, we were able to increase the number of MHC-multimer positive T-cell clones that could be screened for functional activity. However, the failure to isolate high-avidity T-cells for the previously identified LB-NISCH-1A MiHA indicates that isolation of high avidity T-cells may still be a matter of chance [13] . Alternatively, T-cells may be tolerant for some MiHA due to molecular mimicry with non-polymorphic epitopes or due to their failure to discriminate between both allelic variants of a SNP encoding MiHA [27] , explaining why not all MiHA-candidates will be of clinical relevance. that T-cells demonstrating lower dissociation rates confer significantly better antigen specific reactivity than those with fast dissociation rates [28, 31] .
For the high throughput isolation of antigen specific T-cells using recombinant MHC-peptide complexes the use of MHC-multimer complexes is necessary,since MHC-monomers do not stably bind to TCRs. However, multimerization of MHC-peptide complexes may false positively increase the binding avidity of the multimer- approach to identify MiHA that are not frequently induced in vivo but can potentially be used for immunotherapeutic strategies. In addition, these results demonstrate that this approach will enable the identification of clinically relevant MiHA when MiHA candidates are selected based on a hematopoietic restricted gene expression pattern.
Supplemental Figure 1 . The HLA-binding affinity of 25 eluted highly potential MiHA candidates was analyzed by a binding assay that is based on HLA-recovery after UV-exchange monomer technology. After UV-exchange the HLAmonomer rescue score was normalized to the peptides CMV PP65-NLV and CMV PP65-TPR that exhibit a high binding affinity for HLA-A*0201 or B*0702, respectively. Peptides with a higher HLA-recovery score (>40%) compared to the low affinity HLA-A*0201 binding MART1-WT-AAG were selected for further analysis. As negative control no rescue peptide was added. All control peptides are indicated in grey. The percentage of HLA-recovery as a measure for HLA-binding affinity for 9 HLA-A*0201 (a) and 16 HLA-B*0702 (b) restricted MiHA candidates was shown. MiHA candidates with HLA-recovery score above the selection threshold of 40% are indicated in black. MiHA candidates that demonstrated a HLA-recovery below 40% were removed from the study and are indicated with stripes. (C and D) Gene expression of CLYBL and TEP1 were analyzed. Normal hematopoietic T-cells, monocytes, B-cells and hematopoietic stem cells (HSC) were isolated from (G-CSF mobilized) peripheral blood and bone marrow mononuclear cells (PBMC and BMMC) from donors by flowcytometry cell sorting based on expression of CD3, CD14, CD19 and CD34, respectively. Skin derived fibroblasts (FB), keratinocytes (KC) and PTEC were cultured with and without IFN-γ (100 IU/ ml) and hepatocytes were freshly isolated from liver specimen. AML, ALL and CML cells were isolated from peripheral blood and bone marrow samples from patients by flowcytometry cell sorting based on expression of CD33, CD19 and CD34, respectively. EBV-LCL and PHA blasts were generated using standard procedures. Total RNA was isolated and whole-genome gene expression assay was performed as previously described (26) . The probe fluorescence for the (a) CLYBL and (b)TEP1 genes is shown for each sample, and the mean with SD is indicated for each cell type. Supplemental Table 3 . 
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